最新ニュース Upexi (NASDAQ:UPXI) 株価情報

Upexi

Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.

Upexi Inc

News

U.S. CBP: Chinese Imports Eligible For Temporary Duty Exemptions Will Be Subject To Additional 10% U.S. Tariff -Federal Register

JP Morgan analyst Andrea Teixeira maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $103 to $97.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $97

JP Morgan analyst Casey Woodring maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and lowers the price target from $215 to $175.

JP Morgan Maintains Neutral on Charles River, Lowers Price Target to $175

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Constellation Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)</h3>
<ul>
<li>On Monday, Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target to $200. The company' stock fell around 20% over the past month and has a <a href="https://www.benzinga.com/quote/STZ">52-week low of $166.02</a>.</li>
<li>RSI Value: 28.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>STZ Price Action: Shares of Constellation fell 2.1% to trade at $177.09 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">latest STZ news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9.png" alt="" class="wp-image-763223" style="width:531px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133654/image-9-768x707.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">J &amp; J Snack Foods Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>J &amp; J Snack Foods will release its fiscal 2025 first quarter financial results, after the closing bell today. The company's stock fell around 13% over the past month and <a href="https://www.benzinga.com/quote/JJSF">has a 52-week low</a> of $132.88.</li>
<li>RSI Value: 23.4</li>
<li>JJSF Price Action: Shares of J &amp; J Snack Foods dipped 3.2% to trade at $132.88 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">JJSF stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10.png" alt="" class="wp-image-763224" style="width:515px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133803/image-10-768x694.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">elf Beauty Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>)</h3>
<ul>
<li>LiveWire Group will release its fourth quarter and year-end financial results before the opening bell on Wednesday, Feb. 5. The company's stock fell around 25% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ELF">low of $92.20</a>.</li>
<li>RSI Value: 26.4</li>
<li>ELF Price Action: Shares of elf Beauty fell 5.3% to trade at $94.57 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">ELF shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="890" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11.png" alt="" class="wp-image-763227" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11.png 890w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03133854/image-11-768x731.png 768w" sizes="(max-width: 890px) 100vw, 890px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Long Ideas

Markets

Trading Ideas

JJSF

Top 3 Risk Off Stocks That May Surge This Quarter

Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading lower on Monday following President Donald Trump&#8217;s announcement that tariffs on all products from Canada, Mexico and China will take <a href="https://www.benzinga.com//node/43435750">effect on Tuesday</a>.
The Details: According to <a href="https://edition.cnn.com/2025/02/01/economy/trump-tariffs-mexico-canada-china-increased-costs/index.html">CNN</a>, Trump imposed a 25% tariff on all imported goods from Canada and Mexico, along with an additional 10% tariff on goods from China. Energy exports from Canada, however, will be subject to a reduced tariff of 10%.
Trump has since paused his tariffs on Mexico for a month after Mexican President Claudia Sheinbaum agreed to send troops to the border, per <a href="https://www.cnbc.com/2025/02/03/trump-tariffs-mexico-canada-china-sheinbaum-responds.html">CNBC</a>.
The tariffs are expected to impact the auto industry significantly. Last year, the U.S. imported roughly $87 billion in motor vehicles and $64 billion in vehicle parts from Mexico, excluding December. From Canada, the U.S. imported around $34 billion in motor vehicles between January and November.
The electric vehicle industry may be particularly affected, as companies could depend on imported components like batteries and semiconductors. These increased costs may ultimately be passed on to consumers.
Trump reportedly stated that while Americans might feel &#8220;some short-term pain&#8221; from the tariffs, in the long run, the U.S. has been &#8220;ripped off by virtually every country.&#8221;
In response, Canadian Prime Minister Justin Trudeau has retaliated by imposing tariffs on American products. Specifically, Trudeau announced a 25% tariff on around $105 billion worth of U.S. goods. 
What Else: Last week, Tesla announced <a href="https://www.benzinga.com//node/43321103">fiscal results</a> for the 2024 fiscal-year and fourth-quarter. For the fourth-quarter, Tesla reported adjusted earnings per share of 73 cents, missing analysts estimate of 76 cents. In addition, the company announced sales of $25.70 billion, missing analysts estimate of $27.26 billion.
Tesla also reported a 7% year-over-year decline in fourth-quarter production, while deliveries increased by 2% compared to the same period last year.
Related Link: <a href="https://www.benzinga.com/25/02/43440939/chipotle-mexican-grill-q4-earnings-preview-new-store-figures-comparable-sales-on-watch">Chipotle Mexican Grill Q4 Earnings Preview: New Store Figures, Comparable Sales On Watch</a>
TSLA Price Action: At the time of writing, Tesla stock is trading 6.00% lower at $380.19, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

Movers

TSLA

What's Going On With Tesla Stock Monday?

JP Morgan analyst Seth Seifman maintains Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) with a Underweight and lowers the price target from $142 to $140.

JP Morgan Maintains Underweight on Booz Allen Hamilton, Lowers Price Target to $140

JP Morgan analyst Jeffrey Zekauskas maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Overweight and raises the price target from $370 to $390.

JP Morgan Maintains Overweight on Sherwin-Williams, Raises Price Target to $390

JP Morgan analyst Melissa Wedel maintains Runway Gwth Fin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) with a Neutral and raises the price target from $10.5 to $11.

RWAY

JP Morgan Maintains Neutral on Runway Gwth Fin, Raises Price Target to $11

JP Morgan analyst Tami Zakaria maintains Middleby (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) with a Underweight and raises the price target from $134 to $145.

MIDD

JP Morgan Maintains Underweight on Middleby, Raises Price Target to $145

JP Morgan analyst Richard Shane maintains FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) with a Neutral and raises the price target from $20 to $22.

JP Morgan Maintains Neutral on FS KKR Capital, Raises Price Target to $22

WIIM

Olin Corp shares are trading lower after multiple firms cut their respective price targets on the stock.

Trump Trade Adviser Navarro Says It's Going To Take Some Time To Get To Where We Need To Go On Canada

Cleveland-Cliffs shares are trading lower after Morgan Stanley cut its price target on the stock from $13 to $11.

JP Morgan analyst Anthony Elian maintains First Hawaiian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHB#NASDAQ">FHB</a>) with a Underweight and raises the price target from $27 to $29.

JP Morgan Maintains Underweight on First Hawaiian, Raises Price Target to $29

Scotiabank analyst Maher Yaghi downgraded Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) from Sector Outperform to Sector Perform and lowered the <a target="_blank" href="https://www.benzinga.com/quote/CMCSA/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$48&nbsp;to&nbsp;$44.50</a>.
Comcast announced a new strategy to capitalize on the increasing demands for convergence, with a goal of boosting its current 12% wireless/broadband penetration.
In 2025, the company plans to push harder by packaging mobile services with higher-tier broadband products.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43335926/comcast-q4-earnings-beats-estimates-peacock-subscribers-surge-29-dividend-raised-15-billion-buyback-approved" rel="noreferrer noopener">Comcast Q4 Earnings Beat Estimates: Peacock Subscribers Surge 29%, Dividend Raised, $15 Billion Buyback Approved</a>
New and select existing broadband customers picking internet speeds of 300MB or higher will receive a free wireless line. While Yaghi noted this could dilute ARPUs, management is optimistic that broadband ARPU growth will remain healthy in 2025. Additionally, the company highlighted a continued focus on network upgrades to support more potent, integrated products across mobile and broadband. Management emphasized offering simplified bundles and pricing structures, a previous pain point, for new and existing customers.
Comcast reported 139K in domestic broadband losses during the quarter (versus -34K previous year), worse than Yaghi&#8217;s -105K and consensus of -95K. As management highlighted in the previous quarter, weak loading was likely due to impacts from the two hurricanes, which have adversely affected their cable systems and the seasonal tailwind of viewers returning to the Southeast.
Broadband continues to operate in a very competitive market as it competes with fiber and FWA offerings. Still, the company expects the new broadband/mobile converged strategy, as discussed above, to help acquire new customers and retain existing ones. The offering has yet to be rolled out nationwide, so Yaghi does not expect the first half of 2025 net adds to show any material improvement.
Yahi noted that Comcast is growing faster than many peers due to three of its profitable and growing business units. The analyst also noted that fiber competition from incumbents is unlikely to cause significant pain in the short to medium term in the U.S. and that wireless could be the biggest driver for the stock in the medium to long term.
He also noted that its theme parks and media assets are cyclical and exposed to U.S. economic weakness. However, considering the relatively small size of these assets, Yaghi mentioned that Comcast has already priced in some risks, given the stock&#8217;s currently low multiples.
Comcast bleeds broadband customers due to Fixed Wireless Access&nbsp;(FWA) and increasing fiber competition.
Comcast intends to begin offering combo plans to customers using the internet at speeds above those provided by FWA services, with a free wireless line as a retention tool to protect market share.
While this strategy will dilute ARPU and margins, management expects to garner lowered churn rates on broadband as a result.
The U-turn on broadband strategy will likely pressure FCF generation and is not guaranteed to protect broadband market share in the long term.
As a result of this more aggressive pricing strategy, Yaghi reduced his multiple to the connectivity business from 7.0 to 6.5x, resulting in a lowered target price and rating. The analyst expects the stock to remain pressured until markets see signs of stabilization on broadband loading.
Yaghi projected first-quarter revenue of $29.97 billion and adjusted EPS of $1.02.
CMCSA Price Action: Comcast stock was down 0.88% at $33.37 at the last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/43390140/charter-q4-earnings-beats-estimates-mobile-growth-surges-with-529k-new-lines-despite-broadband-subscriber-losses" target="_blank" rel="noreferrer noopener">Charter Beats Earnings Estimates: Mobile Growth Surges, Broadband Subscriber Losses, Network Investments, Mobile &amp; Ad Sales Increase</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Downgrades

CMCSA

Comcast Faces Broadband Headwinds, Analyst Downgrades Stock And Cuts Price Forecast

JP Morgan analyst Jeffrey Zekaukas maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and raises the price target from $110 to $112.

JP Morgan Maintains Overweight on Eastman Chemical, Raises Price Target to $112

LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) reported better-than-expected fourth-quarter 2024 <a href="https://www.benzinga.com/quote/lyb/earnings">sales on Friday</a>.
LyondellBasell reported revenues of $9.497 billion, down 4.4% year-over-year and above the consensus of $9.225 billion. Adjusted EPS was at 75 cents, which is in-line with the consensus.
"The volumes of our sustainable products are rapidly growing and aligned with our profitability targets. We are sharpening our focus on value creation while diligently managing and tracking our progress through a highly disciplined Value Enhancement Program. With a robust investment-grade balance sheet, LYB is well-positioned to deliver on our strategic promises and reward shareholders with a growing dividend as part of our overall value proposition," commented LyondellBasell CEO Peter Vanacker.
For 2025, the company said it anticipates seasonal demand improvements in the first quarter of 2025, supported by lower interest rates, moderate inflation, and rising durable goods consumption.
The company aligns operations with global demand, expecting Olefins &amp; Polyolefins Americas at 80%, EAI at 75% and Intermediates &amp; Derivatives at 80%.
LyondellBasell shares fell 0.2% to trade at $75.53 on Monday.
These analysts made changes to their price targets on LyondellBasell following earnings announcement.
<ul>
<li>Wells Fargo analyst Michael Sison maintained LyondellBasell with an Overweight and lowered the price target from $95 to $90.</li>
<li>UBS analyst Joshua Spector maintained LyondellBasell with a Neutral and lowered the price target from $77 to $76.</li>
<li>Barclays analyst Michael Leithead maintained the stock with an Equal-Weight and cut the price target from $90 to $80.</li>
</ul>
Considering buying LYB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03132838/image-2-1-1024x601.png" alt="" class="wp-image-763207" style="width:537px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03132838/image-2-1-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03132838/image-2-1-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03132838/image-2-1-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03132838/image-2-1.png 1101w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

These Analysts Slash Their Forecasts On LyondellBasell Industries After Q4 Results

JP Morgan analyst Melissa Wedel maintains Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) with a Underweight and raises the price target from $16 to $17.

CGBD

JP Morgan Maintains Underweight on Carlyle Secured Lending, Raises Price Target to $17

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 24 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $105,465, and 21 are calls, for a total amount of $1,655,712.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $210.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $210.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738607428_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.7</td>
<td>$4.55</td>
<td>$4.56</td>
<td>$195.00</td>
<td>$615.5K</td>
<td align="right">546</td>
<td>1.4K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$15.5</td>
<td>$14.2</td>
<td>$15.3</td>
<td>$175.00</td>
<td>$84.1K</td>
<td align="right">225</td>
<td>171</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$16.1</td>
<td>$14.6</td>
<td>$15.15</td>
<td>$175.00</td>
<td>$83.3K</td>
<td align="right">225</td>
<td>61</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$10.9</td>
<td>$10.1</td>
<td>$10.1</td>
<td>$180.00</td>
<td>$77.7K</td>
<td align="right">529</td>
<td>22</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/07/25</td>
<td>$16.85</td>
<td>$16.2</td>
<td>$16.58</td>
<td>$172.50</td>
<td>$72.9K</td>
<td align="right">200</td>
<td>45</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Trading volume stands at 4,545,253, with ABBV's price up by 3.15%, positioned at $189.7.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 81 days.</li>
</ul>
<h3>What Analysts Are Saying About AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $208.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $220. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on AbbVie with a target price of $190. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $211. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $205. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on AbbVie with a target price of $217. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

ABBV

Looking At AbbVie's Recent Unusual Options Activity

Upexi to take action against apparent stock manipulation of fractional share roundup with reverse stock split

10:52 EDT Upexi (UPXI) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try No...

Upexi trading resumes

10:47 EDT Upexi (UPXI) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving breaki...

Upexi trading halted, volatility trading pause

Upexi receives non-compliance notice from Nasdaq stock market

Upexi (UPXI) received a Non Compliance Letter from The Nasdaq Stock Market due to the Company's failure to timely file its Form 10-Q Quarterly Repo...

Upexi receives non-compliance notice from Nasdaq

Upexi (UPXI) has filed a complaint in the United States District Court for the District of Nevada to pursue the groups and individuals who orchestr...

Upexi files litigation over 'manipulation of fractional share roundups'

Upexi (UPXI) announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On Novembe...

Upexi regains compliance with Nasdaq

Upexi regains Nasdaq compliance

Upexi (UPXI) announced establishing a digital currency holding company to invest and capitalize on the opportunities of cryptocurrency including bi...

Upexi establishes digital currency holding company to invest in crypto

Upexi (UPXI) has added James Altucher to advise on its newly announced digital currency holding company, which invests in bitcoin and other coins w...

Comments

Upexi

ニュース

最新ニュース Upexi (NASDAQ:UPXI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル